Comparative Pharmacology
Head-to-head clinical analysis: DIAZEPAM versus NAYZILAM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DIAZEPAM versus NAYZILAM.
DIAZEPAM vs NAYZILAM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Benzodiazepine that enhances GABA-A receptor activity by increasing the frequency of chloride channel opening, leading to neuronal hyperpolarization and inhibition.
Nayzilam (midazolam) is a benzodiazepine that enhances the effect of the neurotransmitter gamma-aminobutyric acid (GABA) at the GABA-A receptor, resulting in increased chloride ion conductance, neuronal hyperpolarization, and inhibition of neuronal activity.
Anxiety: 2-10 mg PO BID-QID; Sedation/Muscle spasm: 5-10 mg IV/IM q3-4h PRN; Status epilepticus: 0.15-0.2 mg/kg IV (max 10 mg) q10-15 min PRN.
5 mg intranasally as a single dose; may repeat once after 10 minutes if needed. Maximum 10 mg per episode.
None Documented
None Documented
Clinical Note
moderateDiazepam + Fluticasone propionate
"The risk or severity of adverse effects can be increased when Diazepam is combined with Fluticasone propionate."
Clinical Note
moderateFludiazepam + Fluticasone propionate
"The risk or severity of adverse effects can be increased when Fludiazepam is combined with Fluticasone propionate."
Clinical Note
moderateDiazepam + Tenofovir disoproxil
"The metabolism of Tenofovir disoproxil can be decreased when combined with Diazepam."
Clinical Note
moderateTerminal half-life 30-56 hours (range 20-70 hours) in adults; prolonged in elderly (up to 100 hours), neonates (up to 100 hours), and cirrhosis (up to 100+ hours).
Terminal elimination half-life of midazolam is 1.5–2.5 hours, but for NAYZILAM (midazolam nasal spray) the effective half-life for anticonvulsant effect is approximately 2–3 hours due to prolonged absorption; clinical context: used for seizure clusters, duration of effect may persist for 4–6 hours.
Renal (70-80% as metabolites, primarily glucuronide conjugates; <5% unchanged), fecal (10-20% as metabolites), biliary (minor).
Renal excretion as metabolites (primarily glucuronide conjugates) and unchanged drug; approximately 15% recovered in urine as unchanged midazolam, with the remainder as metabolites; <1% excreted in feces via biliary elimination.
Category D/X
Category C
Benzodiazepine
Benzodiazepine
Diazepam + Sulfisoxazole
"The metabolism of Sulfisoxazole can be decreased when combined with Diazepam."